Waterland Private Equity exits Euronext-listed healthcare company Arseus


syringe_medicineNetherlands-based Waterland Private Equity has exited its stake in Euronext-listed scientific R&D company Arseus.

The firm, which previously held a 26.16 per cent stake via Waterland Private Equity Fund IV, sold all of its 8,363,865 share, having previously only planned to sell a 20 per cent stake.

Rotterdam-based Arseus is the former professional health division of Omega Pharma, the Belgian OTC pharmaceutical company. Arseus was spun-out of Omega Pharma in October 2007 through an IPO on Euronext Brussels & Amsterdam. The group employs around 2.300 people in 19 European countries, the US, Brazil and Argentina and generated revenues of €424m in 2010.

Copyright © 2014 AltAssets